Physical Activity (PA) for Multiple Sclerosis

Phase-Based Progress Estimates
Multiple Sclerosis+1 More
Physical Activity (PA) - Other
All Sexes
What conditions do you have?

Study Summary

This trial will test if tDCS + physical activity can help people with MS with walking, mobility, and fatigue. The subjects will be randomly assigned to either the active group or the sham group. Some of the trial may be completed remotely.

Eligible Conditions
  • Multiple Sclerosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 4 Weeks

4 Weeks
Gait Velocity
Stride Length

Trial Safety

Trial Design

2 Treatment Groups

active tDCS+PA
1 of 2
sham tDCS+PA
1 of 2
Experimental Treatment
Non-Treatment Group

80 Total Participants · 2 Treatment Groups

Primary Treatment: Physical Activity (PA) · Has Placebo Group · N/A

active tDCS+PAExperimental Group · 2 Interventions: active tDCS, Physical Activity (PA) · Intervention Types: Device, Other
sham tDCS+PAShamComparator Group · 2 Interventions: sham tDCS, Physical Activity (PA) · Intervention Types: Device, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
active tDCS

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 weeks

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,250 Previous Clinical Trials
743,658 Total Patients Enrolled
22 Trials studying Multiple Sclerosis
2,400 Patients Enrolled for Multiple Sclerosis
Leigh Charvet, MDPrincipal InvestigatorNYU Langone Health
7 Previous Clinical Trials
492 Total Patients Enrolled
6 Trials studying Multiple Sclerosis
417 Patients Enrolled for Multiple Sclerosis

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to walk without an assisting device (i.e.
You are able to use study equipment.
You have access to a quiet and distraction free area.
You have a disability status of 1 to 6.5 on the EDSS
You are clinically stable and stable on treatment with disease modifying agents at least from 6 months.
You are able to perform 10 consecutive daily sessions of tDCS while performing a physical program with baseline and follow-up visits.
You are able to understand the informed consent process and provide consent to participate in the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%